Abstract
Photodynamic therapy (PDT), which involves light excitation of photosensitizers (PSs) to induce tissue destruction, has attracted attention as a potential alternative treatment for malignant brain tumors because of high tumor-to-normal (TN) tissue contrast, low photon energy, and minimal invasion.1,2 The treatment effectiveness of PDT has been demonstrated with Photofrin3, talaporfin sodium,4,5 and 5-aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX).6,7 ALA-induced PpIX is expected to have few side effects. Compared with other PSs, it has a higher TN uptake ratio6,8 and faster discharge from the body within 48 h.9 In addition, for deeply seated brain tumors, interstitial photodynamic therapy (iPDT) with ALA,10,11 which involves insertion of cylindrical light diffusers into tissues to efficiently direct photons to target regions, has been more effective in clinical studies compared with existing standard treatments.12,13 Several clinical studies have demonstrated that iPDT outcomes depend on the light dose, which is determined by the irradiation conditions, such as the number of inserted cylindrical light diffusers, their positions, the light fluence rate, and the irradiation time.13 The relationships between treatment outcomes and treatment conditions should be analyzed for safe and effective use of ALA iPDT. Although further clinical studies might be able to provide these data, the collection of malignant brain tumor cases is difficult because these cancers are rare. In addition, many technical difficulties remain to be overcome in directly measuring the interaction of PSs and light in vivo.14
Funding Information
  • JSPS KAKENHI (19K12822)
  • Japan Society for the Promotion of Science (19K12822)

This publication has 49 references indexed in Scilit: